Praluent 150 mg in 1 mL Auto-Injector
RxNorm 1659161
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1659161 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Praluent 150 mg in 1 mL Auto-Injector.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
1 mL alirocumab 150 mg/ML Auto-Injector [Praluent]
(Atom ID: 7254467)
SYPrescribable
Synonym (SY):
1 mL Praluent 150 mg/ML Auto-Injector
(Atom ID: 7254469)
PSNPrescribable
Prescribable Name (PSN):
Praluent 150 mg in 1 mL Auto-Injector
(Atom ID: 7254468)
SYPrescribable
Synonym (SY):
Praluent 150 mg per 1 mL Auto-Injector
(Atom ID: 7254522)
Patient Education
Alirocumab Injection
Alirocumab injection is used along with diet, alone or in combination with other cholesterol-lowering medications (HMG-CoA reductase inhibitors [statins] or ezetimibe [Zetia, in Liptruzet, in Vytorin]), in adults who have familial heterozygous hypercholesterolemia (an inherited condition in which cholesterol cannot be removed from the body normally) to decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood. It is also used in adults with cardiovascular disease to lower the risk of stroke, heart attack, or serious or life-threatening chest pain. Alirocumab injection is also used with other medications to treat homozygous familial hypercholesterolemia (HoFH; an inherited condition in which cholesterol cannot be removed from the body normally) in adults to decrease LDL cholesterol. Alirocumab injection is in a class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor monoclonal antibodies. It works by blocking the production of LDL cholesterol in the body therefore decreasing the amount of cholesterol that may build up on the walls of the arteries. Accumulation of cholesterol along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and, therefore, the oxygen supply to your heart, brain, and other parts of your body.
[Learn More]
* Please review the disclaimer below.